MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

ImmunityBio Inc

Cerrado

SectorSanidad

3.05 4.1

Resumen

Variación precio

24h

Actual

Mínimo

2.89

Máximo

3.12

Métricas clave

By Trading Economics

Ingresos

27M

-59M

Ventas

1.4M

7.6M

BPA

-0.08

Margen de beneficios

-783.62

Empleados

680

EBITDA

946K

-40M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+99.34% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

273M

2.7B

Apertura anterior

-1.05

Cierre anterior

3.05

Noticias sobre sentimiento de mercado

By Acuity

21%

79%

47 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

ImmunityBio Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

29 ene 2025, 15:59 UTC

Principales Movimientos del Mercado

ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene

23 abr 2024, 10:51 UTC

Principales Movimientos del Mercado

ImmunityBio Shares Soar Premarket on FDA Nod for Anktiva

24 oct 2024, 13:50 UTC

Adquisiciones, fusiones, absorciones

This Biotech Stock Could Rocket 800%, Analyst Says -- Barrons.com

Comparación entre iguales

Cambio de precio

ImmunityBio Inc previsión

Precio Objetivo

By TipRanks

99.34% repunte

Estimación a 12 Meses

Media 6.08 USD  99.34%

Máximo 8 USD

Mínimo 4.25 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para ImmunityBio Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

3 ratings

2

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

2.92 / 3.26Soporte y Resistencia

Corto Plazo

Very Strong Bullish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

47 / 386 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de ImmunityBio Inc

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.